190 related articles for article (PubMed ID: 23765106)
1. Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing.
Forsyth CM; Juan V; Akamatsu Y; DuBridge RB; Doan M; Ivanov AV; Ma Z; Polakoff D; Razo J; Wilson K; Powers DB
MAbs; 2013; 5(4):523-32. PubMed ID: 23765106
[TBL] [Abstract][Full Text] [Related]
2. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.
Tiller KE; Li L; Kumar S; Julian MC; Garde S; Tessier PM
J Biol Chem; 2017 Oct; 292(40):16638-16652. PubMed ID: 28778924
[TBL] [Abstract][Full Text] [Related]
3. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
4. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
[TBL] [Abstract][Full Text] [Related]
5. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
[TBL] [Abstract][Full Text] [Related]
6. A general approach to antibody thermostabilization.
McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM
MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312
[TBL] [Abstract][Full Text] [Related]
7. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
[TBL] [Abstract][Full Text] [Related]
8. Humanized antibody neutralizing 2009 pandemic H1N1 virus.
Shembekar N; Mallajosyula VV; Chaudhary P; Upadhyay V; Varadarajan R; Gupta SK
Biotechnol J; 2014 Dec; 9(12):1594-603. PubMed ID: 25044602
[TBL] [Abstract][Full Text] [Related]
9. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.
Lee CV; Koenig P; Fuh G
MAbs; 2014; 6(3):622-7. PubMed ID: 24618680
[TBL] [Abstract][Full Text] [Related]
10. Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies.
Hu D; Hu S; Wan W; Xu M; Du R; Zhao W; Gao X; Liu J; Liu H; Hong J
PLoS One; 2015; 10(6):e0129125. PubMed ID: 26046845
[TBL] [Abstract][Full Text] [Related]
11. Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
Koenig P; Lee CV; Sanowar S; Wu P; Stinson J; Harris SF; Fuh G
J Biol Chem; 2015 Sep; 290(36):21773-86. PubMed ID: 26088137
[TBL] [Abstract][Full Text] [Related]
12. Understanding differences between synthetic and natural antibodies can help improve antibody engineering.
Burkovitz A; Ofran Y
MAbs; 2016; 8(2):278-87. PubMed ID: 26652053
[TBL] [Abstract][Full Text] [Related]
13. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
[TBL] [Abstract][Full Text] [Related]
14. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
15. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
16. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
17. Humanization by CDR grafting and specificity-determining residue grafting.
Kim JH; Hong HJ
Methods Mol Biol; 2012; 907():237-45. PubMed ID: 22907355
[TBL] [Abstract][Full Text] [Related]
18. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
19. A Single-Framework Synthetic Antibody Library Containing a Combination of Canonical and Variable Complementarity-Determining Regions.
Maruthachalam BV; El-Sayed A; Liu J; Sutherland AR; Hill W; Alam MK; Pastushok L; Fonge H; Barreto K; Geyer CR
Chembiochem; 2017 Nov; 18(22):2247-2259. PubMed ID: 28884521
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.
Finlay WJJ; Coleman JE; Edwards JS; Johnson KS
MAbs; 2019 Jan; 11(1):26-44. PubMed ID: 30541416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
